4DMedical gains regulatory approval for CT LVAS in Canada
Filed with ASX · · 3 pages · English
Summary by 6ix AI
4DMedical Ltd. has received regulatory approval for its CT Lung Ventilation Analysis Software in Canada, enhancing its product portfolio in the region. This approval adds to existing Canadian approvals for other respiratory imaging products, increasing access to the Canadian healthcare market. The CT LVAS™ technology allows clinicians to assess lung ventilation using standard CT scans, improving diagnosis and monitoring of lung diseases. The company aims to pursue further regulatory approvals in Canada to enhance respiratory care across North America.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Story so far
Earlier from 4DMedical
- Investor presentation - capital raise
- 4DMedical completes Placement & launches underwritten SPP
- Quarterly Activity Report and Appendix 4C for Q2 FY2025
- 4DMedical progresses to a commercial agreement with Qscan
- US DoD to conduct paid CT VQ pilot ahead of FDA submission
Later from 4DMedical
- Share Purchase Plan Offer Booklet
- Appendix 4D and Half-Year Report
- 1H FY2025 Half-year results
- 1H FY2025 Investor Presentation
- 3-year contract extension secured with the Cleveland Clinic
Follow 4DMedical into a list and get an email when it puts out news.
Follow 4DMedical